Gastro Medical News about Hepatitis B, Chronic

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 10/13/09

Chang TT et al. – For responders who discontinued therapy (per protocol), 24–week off–treatment evaluation is presented to provide a more 'complete picture' of what clinicians can expect when treating nucleoside–naïve HBeAg–positive patients with chronic hepatitis B. For patients who discontinued therapy because of nonresponse and subsequently entered the rollover study ETV–901, follow–up results, including resistance profile, are provided.

<< Previous
KRAS Mutation and Microsatellite Instability: Two Genetic Markers...

Next >>
An evaluation of transient elastography in the discrimination of...